{"filing":{"accession_number":"0001213900-26-065810","cik":"0001448431","ticker":"OPRX","company_name":"OptimizeRx Corp","form":"8-K","filing_date":"2026-06-05","report_date":null,"primary_document":"ea0293598-8k_optimize.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1448431/000121390026065810/ea0293598-8k_optimize.htm"},"events":[{"id":3773,"run_id":3310,"accession_number":"0001213900-26-065810","anchor_item_number":"5.02","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"summary":"Theresa Greco, Chief Commercial Officer, is departing OptimizeRx Corporation effective June 15, 2026, pursuant to a separation agreement executed June 1, 2026. While the filing also discloses severance and advisory arrangement terms, the principal disclosed action is the departure of a named executive officer from her role, making exec_departure the most salient classification. The departure of a CCO is material to investors' assessment of the company's commercial leadership and strategy.","company_name":"OptimizeRx Corp","ticker":"OPRX","filing_date":"2026-06-05","items":[{"id":4787,"accession_number":"0001213900-26-065810","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Theresa Greco, Chief Commercial Officer, is departing OptimizeRx Corporation effective June 15, 2026, pursuant to a separation agreement executed June 1, 2026. While the filing also discloses severance and advisory arrangement terms, the principal disclosed action is the departure of a named executive officer from her role, making exec_departure the most salient classification. The departure of a CCO is material to investors' assessment of the company's commercial leadership and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:12:08.554727+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4787,"accession_number":"0001213900-26-065810","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.","event_type":"exec_departure","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"Theresa Greco, Chief Commercial Officer, is departing OptimizeRx Corporation effective June 15, 2026, pursuant to a separation agreement executed June 1, 2026. While the filing also discloses severance and advisory arrangement terms, the principal disclosed action is the departure of a named executive officer from her role, making exec_departure the most salient classification. The departure of a CCO is material to investors' assessment of the company's commercial leadership and strategy.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T20:12:08.554727+00:00","company_name":"OptimizeRx Corp","ticker":"OPRX","filing_date":"2026-06-05"}]}